Journal of Cancer Research and Therapeutics

CASE REPORT
Year
: 2010  |  Volume : 6  |  Issue : 3  |  Page : 362--364

Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status


Ajay Gupta1, Vinod Raina1, Priyam Garg2, Rakesh Kumar3 
1 Department of Medical Oncology, Institute Rotary Cancer Hospital, New Delhi, India
2 Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India
3 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Ajay Gupta
P-41, South Extension-2, New Delhi - 110 049
India

A 54-year-old man, a non-smoker, suffering from metastatic lung adenocarcinoma presented with extensive bilateral pulmonary infiltrates. He was dyspneic at rest. Performance status (PS) was 4. Institution of gefitinib resulted in relief from dyspnea within two weeks. Positron emission tomography done after 10 months revealed only a 2 cm residual lesion. However, the patient stopped therapy on his own and died two months later. An 80-year-old female, a non smoker, presented with metastatic lung adenocarcinoma and right sided pleural effusion. Her PS was 4. She was started on gefitinib. Within four weeks, she showed marked improvement. At six months, she was radiologically documented to be in partial remission. She continues to be asymptomatic at one year follow-up. These are the first reports of dramatic responses to gefitinib when used as front-line therapy in patients with poor performance status from India.


How to cite this article:
Gupta A, Raina V, Garg P, Kumar R. Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status.J Can Res Ther 2010;6:362-364


How to cite this URL:
Gupta A, Raina V, Garg P, Kumar R. Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status. J Can Res Ther [serial online] 2010 [cited 2020 Aug 5 ];6:362-364
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2010;volume=6;issue=3;spage=362;epage=364;aulast=Gupta;type=0